The association of an elevated Th/Ts ratio and lupus anticoagulant with symptomatic osteonecrosis in systemic lupus erythematosus patients
- PMID: 38384449
- PMCID: PMC10879316
- DOI: 10.3389/fimmu.2024.1288234
The association of an elevated Th/Ts ratio and lupus anticoagulant with symptomatic osteonecrosis in systemic lupus erythematosus patients
Abstract
Objective: This study aimed to assess the risk factors for symptomatic osteonecrosis (ON) in systemic lupus erythematosus (SLE) and identify clinical characteristics and laboratory markers for predicting symptomatic ON occurrence in SLE patients.
Methods: Seventy (6.0%) of 1175 SLE patients diagnosed with symptomatic ON were included in this study. An equal number of SLE patients without symptomatic ON, matched in terms of age and gender, were enrolled in the control group. Clinical symptoms, routine laboratory examinations, lymphocyte subsets, and treatments of these patients were retrospectively reviewed and compared between the two groups. Logistic regression analysis was employed to identify risk factors associated with symptomatic ON in SLE.
Results: Among the 70 cases in the symptomatic ON group, 62 (88.6%) patients experienced femoral head necrosis, with bilateral involvement observed in 58 patients. Bone pain was reported in 32 cases (51.6%), and 19 cases (30.6%) presented with multiple symptoms. Univariate analysis revealed significant differences between the two groups in various factors, including disease duration (months), cumulative steroid exposure time, history of thrombosis, neurological involvement, the number of affected organs, myalgia/myasthenia, and the use of medications such as glucocorticoids, immunosuppressants, aspirin, and statins (P<0.05). Moreover, lupus anticoagulant (LA) levels were significantly higher in the symptomatic ON group than in the control group (P<0.05). Furthermore, notable distinctions were observed in peripheral blood immune cells, including an elevated white blood cell count (WBC), a decreased percentage of Ts cells (CD3+CD8+), and an elevated Th/Ts ratio. Logistic regression analysis revealed that a history of thrombosis, LA positivity, and an elevated Th/Ts ratio remained positive factors associated with symptomatic ON (P<0.05).
Conclusion: Decreased Ts cells and changes in the T lymphocyte subset play an important regulatory role in the development of symptomatic ON. A history of thrombosis and LA are associated with an increased probability of symptomatic ON in SLE and may serve as potential predictors.
Keywords: lupus anticoagulant; lymphocyte; risk factors; symptomatic osteonecrosis; systemic lupus erythematosus.
Copyright © 2024 Hou, Lei, Xue, Jing, Mi, Guo, Xu and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.Ann Rheum Dis. 2006 Jun;65(6):785-90. doi: 10.1136/ard.2005.040428. Epub 2005 Nov 3. Ann Rheum Dis. 2006. PMID: 16269429 Free PMC article.
-
Catastrophic antiphospholipid syndromes in systemic lupus erythematosus.Ren Fail. 1999 Jan;21(1):49-61. doi: 10.3109/08860229909066969. Ren Fail. 1999. PMID: 10048117 Review.
-
Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis.Lupus. 2020 Apr;29(5):490-498. doi: 10.1177/0961203320909952. Epub 2020 Mar 4. Lupus. 2020. PMID: 32131675
-
Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.Clin Rheumatol. 2019 Mar;38(3):885-893. doi: 10.1007/s10067-018-4381-y. Epub 2018 Dec 4. Clin Rheumatol. 2019. PMID: 30515663
-
An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus.Biomolecules. 2023 Mar 30;13(4):617. doi: 10.3390/biom13040617. Biomolecules. 2023. PMID: 37189365 Free PMC article. Review.
Cited by
-
The clinical and immunological features of CMV infection in rheumatic patients: a nested case-control study.Clin Rheumatol. 2025 Jul;44(7):3033-3047. doi: 10.1007/s10067-025-07456-2. Epub 2025 May 15. Clin Rheumatol. 2025. PMID: 40374870
-
Avascular Necrosis of the Femoral Head in Patients with Antiphospholipid Syndrome: A Case Series.Hematol Rep. 2025 Mar 21;17(2):15. doi: 10.3390/hematolrep17020015. Hematol Rep. 2025. PMID: 40126224 Free PMC article.
-
Hip joint-preserving strategies for treating osteonecrosis of the femoral head: From nonoperative to operative procedures.J Orthop Translat. 2025 Mar 19;51:256-277. doi: 10.1016/j.jot.2025.02.001. eCollection 2025 Mar. J Orthop Translat. 2025. PMID: 40190345 Free PMC article. Review.
References
-
- Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol (1997) 24(4):654–62. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous